References

Prions

10.1073/pnas.95.23.13363 · 1998 · External reference

A systematic review of prion therapeutics in experimental models

10.1093/brain/awl150 · 2006 · External reference

Prion disease: chemotherapeutic strategies

10.2174/187152612800100161 · 2012 · External reference

Amyloid-binding compounds and their anti-prion potency

10.2174/15680266113136660178 · 2013 · External reference

Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies

10.1099/vir.0.19754-0 · 2004 · External reference

Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies

10.1111/j.1471-4159.2006.04035.x · 2006 · External reference

Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner

10.1128/jvi.01563-07 · 2007 · External reference

Drug resistance confounding prion therapeutics

10.1073/pnas.1317164110 · 2013 · External reference

Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study

10.1212/01.wnl.0000113764.35026.ef · 2004 · External reference

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

10.1016/s1474-4422(09)70049-3 · 2009 · External reference

Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases

10.1111/j.1440-1789.2009.01058.x · 2009 · External reference

Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease

10.1212/wnl.0b013e3182a9f3b4 · 2013 · External reference

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial

10.1016/s1474-4422(13)70307-7 · 2014 · External reference

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

10.1073/pnas.161274798 · 2001 · External reference

New inhibitors of scrapie-associated prion protein formation in a library of 2,000 drugs and natural products

10.1128/jvi.77.19.10288-10294.2003 · 2003 · External reference

Prophylactic effect of dietary seaweed Fucoidan against enteral prion infection

10.1128/aac.00917-06 · 2007 · External reference

Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals

10.1016/j.bbrc.2011.01.030 · 2011 · External reference

Function of antimicrobial proteins in insects

1994 · External reference

Insects antiviral and anticancer peptides: new leads for the future?

10.2174/092986608784966912 · 2008 · External reference

Insect natural products and processes: new treatments for human disease

10.1016/j.ibmb.2011.05.007 · 2011 · External reference

Insect inducible antimicrobial peptides and their applications

10.2174/1389203711209070620 · 2013 · External reference

Purification, characterization, and cDNA cloning of an antifungal protein from the hemolymph of Sarcophaga peregrina (flesh fly) larvae

10.1016/s0021-9258(19)50307-6 · 1993 · External reference

Isolation and characterization of a new member of the insect defensin family from a beetle, Allomyrina dichotoma

10.1006/bbrc.1996.0438 · 1996 · External reference

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation

10.1128/jvi.74.10.4894-4897.2000 · 2000 · External reference

Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D-interacting protein

10.1128/jvi.03775-13 · 2014 · External reference

N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction

10.1021/bi9530550 · 1996 · External reference

Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform

10.1083/jcb.129.1.121 · 1995 · External reference

Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments

10.1111/j.1471-4159.2006.03889.x · 2006 · External reference

Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation

10.1007/s00018-009-0158-4 · 2009 · External reference

Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation

10.1074/jbc.m110.108548 · 2010 · External reference

Live imaging of prions reveals nascent PrPSc in cell-surface, raft-associated amyloid strings and webs

10.1083/jcb.201308028 · 2014 · External reference

Autophagy, prion infection and their mutual interactions

2010 · External reference

Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro

10.1006/jmbi.2000.3840 · 2000 · External reference

Complex polyamines: unique prion disaggregating compounds

10.2174/187152709789541952 · 2009 · External reference

Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells

10.1128/jvi.67.2.643-650.1993 · 1993 · External reference

Properties of phenoloxidase purified from larvae of the housefly

1989 · External reference

Amyloidophilic compounds for prion diseases

10.2174/1871526510909010015 · 2009 · External reference

Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies

10.1074/jbc.m400854200 · 2004 · External reference

Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques

10.1016/s0304-3940(02)00310-5 · 2002 · External reference

Influence of the maillard reaction to prion protein aggregation

10.1089/rej.2009.0954 · 2010 · External reference